KPV (10 mg Vial) Dosage Protocol

Dosing & Reconstitution Overview

KPV (lysine-proline-valine) is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (α-MSH), studied for its anti-inflammatory activity. The figures below are compiled strictly for laboratory and educational reference — they describe how the compound is handled and dosed in published research protocols, not a recommendation for use in humans or animals.

For a 10 mg vial, adding 3.0 mL of bacteriostatic water yields a concentration of roughly 3.33 mg/mL (about 3,333 mcg/mL). At that concentration, each unit drawn on a U-100 insulin syringe equals 0.01 mL and delivers approximately 33.3 mcg of material, which keeps the low-microgram titration steps easy to measure.

Standard (Gradual) Titration Schedule

The gradual schedule steps the daily amount up over the first three weeks before holding at a maintenance level, a pattern used in educational protocols to ease into the working dose band.

Reconstitution Steps

1. Let the sealed lyophilized vial and the bacteriostatic water reach room temperature, then wipe both stoppers with an alcohol swab.
2. Draw 3.0 mL of bacteriostatic water and inject it slowly down the inside wall of the vial — never directly onto the powder pellet.
3. Swirl gently until fully dissolved. Do not shake; aggressive agitation can shear the peptide.
4. The solution should be clear and colourless. Label the vial with the concentration (~3.33 mg/mL) and the reconstitution date.
5. Store upright under refrigeration between uses and draw subsequent volumes with a fresh sterile syringe each time.

Advanced (Maintenance) Schedule

Some educational protocols skip the slow ramp and run a flat maintenance dose once tolerability at a low step is established. This holds the upper end of the published band for the full cycle.

Supplies Needed

• KPV vials (10 mg): ~3 vials for an 8-week run; ~4 vials for 12 weeks; ~6 vials for a 16-week run at the maintenance dose.
• Insulin syringes (U-100, 1 mL): ~56 for 8 weeks, ~84 for 12 weeks, ~112 for 16 weeks (one fresh syringe per daily draw).
• Bacteriostatic water (10 mL): one bottle covers an 8-week run; two bottles for a 12–16 week run.
• Alcohol swabs: ~112 for 8 weeks, ~168 for 12 weeks, ~224 for 16 weeks (vial stopper plus site per dose).

Protocol Overview

• Research goal: model anti-inflammatory activity via NF-κB pathway modulation and cytokine suppression.
• Schedule: once-daily subcutaneous administration in the published educational model.
• Dose band: 200–500 mcg daily.
• Fill: 10 mg lyophilized, reconstituted to ~3.33 mg/mL with 3 mL diluent.
• Storage: −20 °C dry; 2–8 °C once reconstituted.

Dosing Protocol Notes

• Begin at the lowest 200 mcg step and step up weekly while tolerability is assessed.
• Keep administration on a fixed daily cadence and the same time of day where possible for steady exposure modelling.
• Hold the maintenance step (500 mcg) for the bulk of the cycle once the ramp is complete.
• Because doses are small, prefer a syringe with clear unit gradations and verify each draw before administration.

Storage Instructions

Keep sealed lyophilized vials at −20 °C or below, protected from light, where stability extends for many months. Once reconstituted, refrigerate at 2–8 °C and use within about 30 days. Allow refrigerated solution to warm slightly before drawing, avoid repeated freeze-thaw cycles, and aliquot if a vial will be sampled many times.

Important Handling Notes

• Use a sterile syringe for every draw and never re-enter the vial with a used needle.
• Rotate sampling/handling technique to keep the stopper intact.
• Confirm the small microgram volumes carefully, since a one-unit error is a meaningful fraction of the dose.
• Document each draw — date, volume, remaining material — for reproducibility.

How KPV Works

KPV is the C-terminal tripeptide sequence (residues 11–13) of α-MSH, and it retains much of the parent hormone's anti-inflammatory activity while lacking its pigment-stimulating (melanotropic) effects. In the published literature its main proposed mechanism is suppression of nuclear factor kappa B (NF-κB) signalling, the transcription pathway that drives many pro-inflammatory genes. By dampening this pathway, KPV is reported to reduce the release of inflammatory mediators and to limit downstream cytokine production, which is the basis for its study in inflammation and wound-healing models.

Reported Benefits & Side Effects

Benefits observed in research

• Reductions in pro-inflammatory cytokines such as TNF-α, IL-6 and IL-1β in laboratory models.
• Support for wound-healing and tissue-repair processes attributed to its inflammatory modulation.
• Retained anti-inflammatory potency without the melanotropic (skin-darkening) activity of full-length α-MSH.
• Generally well tolerated in the available reports, with systemic effects rarely described.

Side effects reported

• Occasional mild injection-site reactions such as redness or slight swelling.
• Systemic side effects rarely reported in the available literature.
• Tolerability data remain limited and come largely from preclinical and educational sources.

Injection/Handling Technique (Reference Only)

• Clean the vial stopper and the chosen site with alcohol swabs and let them dry for about 10–15 seconds.
• Pinch a 1–2 inch skinfold and insert subcutaneously at a 45–90° angle depending on needle length; aspiration is not required for subcutaneous work.
• Inject slowly over roughly 3–5 seconds.
• Rotate sites systematically — abdomen (at least 2 inches from the navel), anterior or lateral thigh, and outer upper arm — and dispose of sharps in an approved container.

References

Related Protocols